CN102188704B - 使用il-21和单克隆抗体疗法治疗癌症的方法 - Google Patents

使用il-21和单克隆抗体疗法治疗癌症的方法 Download PDF

Info

Publication number
CN102188704B
CN102188704B CN2011101079712A CN201110107971A CN102188704B CN 102188704 B CN102188704 B CN 102188704B CN 2011101079712 A CN2011101079712 A CN 2011101079712A CN 201110107971 A CN201110107971 A CN 201110107971A CN 102188704 B CN102188704 B CN 102188704B
Authority
CN
China
Prior art keywords
cell
rituximab
tumor
mice
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2011101079712A
Other languages
English (en)
Chinese (zh)
Other versions
CN102188704A (zh
Inventor
W·R·金德斯沃格尔
S·D·胡格赫斯
R·D·豪雷
C·H·克雷格
D·C·弗斯特
R·A·约翰逊
M·D·黑佩尔
P·V·斯瓦库玛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymogenetics Inc
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of CN102188704A publication Critical patent/CN102188704A/zh
Application granted granted Critical
Publication of CN102188704B publication Critical patent/CN102188704B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN2011101079712A 2004-05-20 2005-05-20 使用il-21和单克隆抗体疗法治疗癌症的方法 Expired - Fee Related CN102188704B (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US57297304P 2004-05-20 2004-05-20
US60/572,973 2004-05-20
US63538004P 2004-12-10 2004-12-10
US60/635,380 2004-12-10
US67128105P 2005-04-14 2005-04-14
US60/671,281 2005-04-14
US68044705P 2005-05-12 2005-05-12
US60/680,447 2005-05-12

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN 200580021262 Division CN101084012A (zh) 2004-05-20 2005-05-20 使用il－21和单克隆抗体疗法治疗癌症的方法

Publications (2)

Publication Number Publication Date
CN102188704A CN102188704A (zh) 2011-09-21
CN102188704B true CN102188704B (zh) 2013-04-24

Family

ID=34971701

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2011101079712A Expired - Fee Related CN102188704B (zh) 2004-05-20 2005-05-20 使用il-21和单克隆抗体疗法治疗癌症的方法
CN2013100575165A Pending CN103127502A (zh) 2004-05-20 2005-05-20 使用il-21和单克隆抗体疗法治疗癌症的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2013100575165A Pending CN103127502A (zh) 2004-05-20 2005-05-20 使用il-21和单克隆抗体疗法治疗癌症的方法

Country Status (15)

Country Link
US (8) US20050265966A1 (enExample)
EP (4) EP2428216A3 (enExample)
JP (2) JP4982373B2 (enExample)
KR (1) KR101236177B1 (enExample)
CN (2) CN102188704B (enExample)
AU (1) AU2005245031B2 (enExample)
BR (1) BRPI0511187A (enExample)
CA (1) CA2566745A1 (enExample)
CY (1) CY1113287T1 (enExample)
DK (1) DK1758610T3 (enExample)
ES (1) ES2390278T3 (enExample)
IL (1) IL179099A (enExample)
PL (1) PL1758610T3 (enExample)
PT (1) PT1758610E (enExample)
WO (1) WO2005113001A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
CA2566745A1 (en) * 2004-05-20 2005-12-01 Zymogenetics, Inc. Methods of treating cancer using il-21 and monoclonal antibody therapy
US20070218116A1 (en) * 2006-03-14 2007-09-20 Schwendener Reto A Compositions and methods for the treatment of tumors and tumor metastases
AU2007310777A1 (en) 2006-10-26 2008-05-02 Novo Nordisk A/S IL-21 variants
KR100902340B1 (ko) * 2007-08-02 2009-06-12 한국생명공학연구원 Ｙｃ－１ 또는 ｉｌ－２１을 유효성분으로 포함하는자연살해세포 분화제 및 분화 방법
US8506933B2 (en) * 2007-11-30 2013-08-13 Msdx, Inc. Methods of detecting a neurological condition via analysis of circulating phagocytes
EP2464741A4 (en) * 2009-08-10 2013-05-22 Ramesh C Nayak METHODS OF DETECTING RESPONSES TO THERAPIES USING PERFORINE LEVELS
EP2504699A1 (en) * 2009-11-27 2012-10-03 MSDX, Inc. Methods of detecting or monitoring activity of an inflammatory or neurodegenerative condition
US8673309B2 (en) 2011-02-11 2014-03-18 Msdx, Inc. Methods for measuring high molecular weight complexes of fibrinogen with fibronectin and fibulin-1
WO2013109904A1 (en) * 2012-01-19 2013-07-25 University Of Miami Compositions, methods and kits for treatment of cancer and autoimmune diseases
WO2013169693A1 (en) 2012-05-09 2013-11-14 Bristol-Myers Squibb Company Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
KR101453462B1 (ko) 2013-05-16 2014-10-23 앱클론(주) Her2에 특이적으로 결합하는 항체
AU2015244025B2 (en) 2014-04-08 2019-03-21 Boston Pharmaceuticals Inc. Binding molecules specific for IL-21 and uses thereof
KR20160120157A (ko) 2015-04-07 2016-10-17 주식회사 메드팩토 암 예방 또는 치료용 약학적 조성물 및 이를 이용한 방법
WO2018067602A1 (en) * 2016-10-03 2018-04-12 Baylor College Of Medicine Modulating cytotoxic cell lytic granule positioning to promote diffuse killing in cellular therapies
AU2018333062B2 (en) * 2017-09-15 2022-03-17 Beckman Coulter, Inc. Flow based assays for therapeutics
KR102265437B1 (ko) 2017-11-24 2021-06-15 의료법인 성광의료재단 Nk 배양용 조성물 및 이를 이용하여 nk 세포를 배양하는 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2092468T3 (es) 1988-01-22 1996-12-01 Zymogenetics Inc Metodos para producir analogos de receptores secretados.
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6057128A (en) * 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
PT1974747E (pt) 1998-08-11 2012-09-05 Biogen Idec Inc Terapias de combinação para linfomas de células b compreendendo a administração de anticorpo anti-cd20
EP1189931B1 (en) * 1999-07-02 2006-06-21 Genentech, Inc. Peptide compounds that bind her2
IT1311703B1 (it) 1999-07-23 2002-03-19 Sipa Spa Impianto ad alta efficienza di soffiaggio di preforme
ES2279809T3 (es) 2000-04-05 2007-09-01 Zymogenetics, Inc. Receptores de citoquina zalfa11 solubles.
US7306801B2 (en) * 2000-05-15 2007-12-11 Health Research, Inc. Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
AU2002362098A1 (en) 2001-12-07 2003-06-23 Chiron Corporation Methods of therapy for non-hodgkin's lymphoma
CA2476166C (en) * 2002-02-14 2011-11-15 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
NZ536420A (en) * 2002-04-12 2008-04-30 Medarex Inc Methods of treatment using CTLA-4 antibodies
US20040016010A1 (en) * 2002-04-17 2004-01-22 Marion Kasaian IL-21 receptor knockout animal and methods of use thereof
MXPA04012116A (es) * 2002-06-07 2005-04-19 Zymogenetics Inc Uso del il-21 en cancer y otras aplicaciones terapeuticas.
KR20050065587A (ko) * 2002-10-08 2005-06-29 이뮤노메딕스, 인코오포레이티드 항체 치료법
US20070092485A1 (en) * 2002-11-15 2007-04-26 Zymogenetics, Inc. Cytokine zalpha11 ligand
MXPA05006117A (es) * 2002-12-13 2005-09-30 Zymogenetics Inc Produccion de il-21 en hospederos procarioticos.
US7465446B2 (en) 2003-05-30 2008-12-16 Medarex, Inc. Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
EP1680138B1 (en) * 2003-10-17 2013-07-17 Novo Nordisk A/S Combination therapy
CA2566745A1 (en) * 2004-05-20 2005-12-01 Zymogenetics, Inc. Methods of treating cancer using il-21 and monoclonal antibody therapy
EP1814580B1 (en) * 2004-11-24 2016-08-10 Fred Hutchinson Cancer Research Center Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand

Also Published As

Publication number Publication date
PT1758610E (pt) 2012-10-01
AU2005245031A1 (en) 2005-12-01
CN103127502A (zh) 2013-06-05
CN102188704A (zh) 2011-09-21
EP2431050A1 (en) 2012-03-21
CY1113287T1 (el) 2016-04-13
ES2390278T3 (es) 2012-11-08
KR20070026588A (ko) 2007-03-08
DK1758610T3 (da) 2012-10-15
JP2007538108A (ja) 2007-12-27
US20070122382A1 (en) 2007-05-31
EP2431050A8 (en) 2012-09-26
US20090269304A1 (en) 2009-10-29
KR101236177B1 (ko) 2013-02-22
US20070178063A1 (en) 2007-08-02
PL1758610T3 (pl) 2012-11-30
US20090087404A1 (en) 2009-04-02
CA2566745A1 (en) 2005-12-01
EP2425847A1 (en) 2012-03-07
JP2012102122A (ja) 2012-05-31
EP1758610A1 (en) 2007-03-07
EP2428216A9 (en) 2012-04-25
IL179099A0 (en) 2007-03-08
BRPI0511187A (pt) 2007-12-04
US20110300098A1 (en) 2011-12-08
AU2005245031B2 (en) 2011-08-18
WO2005113001A1 (en) 2005-12-01
EP1758610B1 (en) 2012-07-04
US20110086004A1 (en) 2011-04-14
EP2428216A2 (en) 2012-03-14
IL179099A (en) 2011-03-31
US20050265966A1 (en) 2005-12-01
US20070048264A1 (en) 2007-03-01
HK1160776A1 (en) 2012-08-17
EP2428216A3 (en) 2012-05-23
JP4982373B2 (ja) 2012-07-25

Similar Documents

Publication Publication Date Title
Gang et al. CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas
JP7605912B2 (ja) Ｇｐｒｃ５ｄキメラ抗原受容体及びそれを発現する細胞
US20090087404A1 (en) Methods of treating cancer using il-21 and monoclonal antibody therapy
JP2021193150A (ja) 小細胞肺癌に対する標的療法
CN118878692A (zh) 双特异性抗体组合物及其使用方法
US20230172980A1 (en) Chimeric Antigen Receptor, Construction Method Therefor and Application Thereof
EP4445912A1 (en) P329g antibody targeting bcma, combination of same with chimeric antigen receptor cell, and use thereof
TWI908715B (zh) 用於治療疾病之CLEC12AxCD3雙特異性抗體及方法
Miljkovic et al. Interleukin-15 augments NK cell–mediated ADCC of alemtuzumab in patients with CD52+ T-cell malignancies
CN101084012A (zh) 使用il－21和单克隆抗体疗法治疗癌症的方法
Arora T Cells enhance Natural Killer Cell antibody dependent cellular cytotoxicity
HK1160776B (en) Methods of treating cancer using il-21 and monoclonal antibody therapy
Snyder Augmenting Natural Killer cell antibody binding to enhance ovarian and prostate tumor cell killing via ADCC
CN118924893A (zh) Bcmap329g抗体及car-t细胞在治疗多发性骨髓瘤中的应用
HK1167338A (en) Methods of treating cancer using il-21 and monoclonal antibody therapy
HK1167803A (en) Methods of treating cancer using il-21 and monoclonal antibody therapy
HK1167337A (en) Methods of treating cancer using il-21 and monoclonal antibody therapy
Burlion et al. A novel combination of cyclophosphamide and anti-ICOS mAb prevents tumor growth by affecting regulatory T cells in mice with a human immune system

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1160776

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1160776

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130424

Termination date: 20160520

CF01 Termination of patent right due to non-payment of annual fee